Induction of hyperplasia and increased DNA content in the uterus of immature rats exposed to coumestrol. by Ashby, J et al.
Articles
Induction of Hyperplasia and Increased DNA Content in the Uterus of
Immature Rats Exposed to Coumestrol
John Ashby, Helen Tinwell, Anthony Soames, andJohn Foster
Zeneca Central Toxicological Laboratory, Alderley Park, Macclesfield, Cheshire, United Kingdom
Administration ofthe phytoestrogen coumestrol to ovariectomized rats leads to increases in both
wet and dry uterine weights in the absence ofan increase in uterine DNA content, as reported by
Markaverich et aL [Effects ofCoumestrol on Estrogen Receptor Function and Uterine Growth in
Ovariectomized Rats. Environ Health Perspect 103:574-581 (1995)]. Itwas notpossible toknowif
the observed atypical uterotrophic response ofcoumestrol was associateduniquelywith the ovariec-
tomized uterotrophic assay protocoL This question is answered in the:present paper. Two experi-
ments aredescribedinwhich threedailyoral gavage administrations of60 mg/kg/daycoumestrol to
immature AP rats were followed byassessment ofthe reproductive tract on the fourth day. In both
experiments coumestrol increased uterine fluid content and increased the weights ofthe uterus,
cervix, and vagina. In addition, bromodeoxyuridine staining ofuterine sections enabled confima-
tion ofuterine hyperplasia for thecoumestrol-treated animals. Inthesecond exriment, total uter-
ine DNAwas determined; itdoubledinthecounestol-treated animals.Estradiolbenzoateactedas
thepositive control agent for both oftheseexperiments, and in each case it gave similar responses to
those seen for coumestrol. We condude that the uterophic actvity ofthe phytoestrogen coume-
strol in the immature intact rat is typical oftheactivity ofthenatural estogen estradiol. Keywords:
coumestrol, DNA synthesis, hyperplasias imur, rodent, ovariectomized, uterotrophic. Environ
Healst Perspect107:819-822 (1999). [Online 3 September 1999]
bttp.:/ehpnetl.niehs.nih.gov/ldcs/l999/107p819-822ashby/abstract.html
Markaverich et al. (1) reported that adminis-
tration of the phytoestrogen coumestrol
(COUM) to ovariectomized rats, either as a
single subcutaneous injection or via drinking
water for 5 days, leads to increases in both
wet and dry uterine weights. However, these
tissue weight increases were not considered
to be caused by cellular hyperplasia because
there was no commensurate increase in
DNA content of the uteri. These results
were in contrast to those seen by other inves-
tigators for COUM when using the imma-
ture intact rat uterotrophic assay (2,3),
although Markaverich et al. (1) noted that
whether or not COUM induces cellular
hyperplasia and increases in DNA content in
those earlier studies was not evaluated.
Given the increasing reliance on the
rodent uterotrophic assay as a primary mea-
sure ofthe estrogenic activity ofchemicals to
rodents, the prospect that some agents that
are active in this assay may not have caused
uterine hyperplasia is worthy of further
study. Because we recently confirmed the
activity of COUM in the immature rat
uterotrophic assay (4), we repeated and
extended those experiments to include an
assessment of uterine hyperplasia (bromod-
eoxyuridine staining) and total uterine DNA
content. In addition, the surgical procedure
was modified to enable accurate determina-
tion of uterine luminal fluid content and to
enable monitoring ofpossible changes to the
weight of the cervix and vagina. The pre-
sumed involvement of the estrogen receptor
(ER) in the uterotrophic activity of COUM
was evaluated by conducting experiments in
the presence and absence ofthe ER blocking
agent Faslodex (FAS; ICI 182,780; Zeneca
Pharmaceuticals, Macclesfield, Cheshire,
UK) (5). Estradiol benzoate (E2B) was used
as a positive control for these experiments.
Materials and Methods
Chemicals. COUM, E2B, FAS, and arachis
oil (AG) were used as previously described
(4). 5-Bromodeoxyuridine (BrdU), 3,3'-
diaminobenzidine, orcinol, and calf thymus
DNA were obtained from Sigma Chemical
Company (Poole, Dorset, UK). All antibod-
ies were supplied by DAKO Ltd. (High
Wycombe, UK). Yeast RNA was purchased
from Calbiochem (Nottingham, UK).
Animals. Immature female Alpk:AP rats
(21-22 days old) with body weights in the
range of 38-48 g were obtained from the
breeding unit at Zeneca, Alderley Park
(Macclesfield, Cheshire, UK). Animals were
housed in wire mesh cages with solid bot-
toms. Humidity and temperature were con-
trolled and a 12-hr/12-hr light-dark cycle
was maintained. Animals were weaned on
R&M No. 3 diet at 19-21 days old and
maintained on R&M No. 1 diet from 21
days onward (both diets were obtained from
Special Diet Services Ltd., Witham, Essex,
UK). Diet and water were available ad libi-
tum. All animals were acclimatized for 24 hr
before being dosed.
Uterotrophic assays. The uterotrophic
activities of COUM, E2B, and FAS were
evaluated using the test protocol described by
Odum et al. (4). The test agents were dis-
solved (E2B) or homogeneously suspended
(4) (COUM and FAS) in AO and dosed by
oral gavage on 3 successive days. Each animal
received either two doses (one immediately
following the other) ofthe appropriate com-
pound combination/day (experiment 1,
Table 1) or a single dose of the appropriate
compound (experiment 2, Table 1) using a
dosing volume of5 ml/kg body weight. AO-
dosed animals acted as vehicle controls.
Animals were sacrificed using an overdose of
Fluothane (Zeneca Pharmaceuticals) fol-
lowed by cervical dislocation 24 hr after the
final dose. Vaginal opening (or otherwise)
was recorded at the time of death. Test
groups, daily dose levels, and animal group
sizes are shown in Table 1. In the first experi-
ment BrdU was administered in the drinking
water [0.8 mg/mL, based on the method of
Carthew et al. (6] for the duration of the
experiment. The BrdU solution was con-
tained in glass drinking bottles covered in
aluminum foil to reduce photodecomposi-
tion ofthe BrdU.
The reproductive tract was excised from
the junction of the uterine horns with the
ovaries to the external involution ofthe vagi-
na, trimmed free offat, and weighed without
puncturing the uterus. The vagina was
removed and weighed. The cervix was
removed and discarded. The remaining
uterus (intact uterus) wasweighed again prior
to being punctured, blotted to remove excess
water, and reweighed [uterine wetweight; (4)
and as described here]. The uterus was then
cut such that the right horn could be dried at
700C for 24 hr (4) and reweighed to obtain a
dry weight (adjusting the uterine weight to
give total uterine dry weight). The left horn
of the uterus, together with the junction to
the cervix, was processed for either BrdU
staining (experiment 1) or total DNA con-
tent determination (experiment 2). From
these measurements the uterine luminal fluid
was also calculated. Cervical weight was
determined by default based on the recorded
weight ofthe entire reproductive tract minus
the recorded weights of both the vagina and
the intact uterus (prior to blotting).
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Determination ofuterine hyperplasia.
The left uterine horn together with the junc-
tion to the cervix from each animal was fixed
in 10% formal saline and processed to paraf-
fin wax. Longitudinal sections were stained to
reveal BrdU (2-) as follows. The sections were
trypsinized, the DNA denatured, and the
endogenous peroxidase activity blocked. The
sections were then incubated with normal
goat serum followed by anti-BrdU antibody,
washed, incubated with goat antimouse
immunoglobulins, washed, and incubated
with Strep A B complex/horseradish peroxi-
dase. The sections were developed with 3,3
diaminobenzidene and counter-stained with
Mayer's hematoxylin. The percentage labeling
index was determined for epithelial cells of
the uterine lumen andglands and for the stro-
ma (500 cells per animal assessed where possi-
ble). Endometrial and epithelial thickness
were assessed at 10 locations for each animal.
Determination ofuterine DNA content.
The left uterine horn and its junction to the
cervix from each animal was homogenized for
10-15 sec in 1 mL chilled physiological saline
using an Ultra-Turrax UJanke and Kunkel
IKA-Labortechnik, Stauffen, Germany).
Hydrolyzed uterine total nucleic acid was iso-
lated as follows using trichloroacetic acid
(TCA) (8). Chilled 10% TCA (0.5 mL) was
added to an equal volume of homogenate,
vortexed, and incubated on ice for 30 min.
This mixture was spun at 600g at 40C for S
min, the supernatant carefully removed, and
the pellet was washed twice using 1 mL
chilled 5% TCA. The nucleic acid was
hydrolyzed in a further 1 mL 5% TCA at
900C for 30 min. This mixture was cooled to
40C on ice before centrifuging at 600gat 4'C
for 15 min. Duplicate dilutions ofeach super-
natant (1:30 in 5% TCA) were prepared and
were allowed to reach room temperature
before determining their hydrolyzed nucleic
acid content using an optical density (OD) of
260 nm. Known quantities of calf thymus
DNA were handled in an identical manner
(with the exception of the homogenization
Table 2. Hypertrophy of the endometrium and
luminal epithelium in the immature rat following
treatment with E13, COUM, or FAS.
Test agent and
daily dose level Endometrium" Epithelium"9
AO (5 mL/kg) 126.4 ± 23.6 8.5 ± 1.3
E28 (400 pg/kg) 225.6 ± 42.8** 42.8±98*0
COUM (60 mg/kg) 231.3 ± 45.7** 22.1 ± 4.7**
COUM 160 mg/kg) 120.5 ± 16.6## 8.7 ± 1.8##
+ FAS (10 mg/kg)
FAS(110 mg/kg) 100.4 ± 25.5 9.2 ± 2.0
Abbreviations: AO, arachis oil; COUM, coumestrol; E2B,
estradiol benzoate; FAS, Faslodex (ICI 182,780; Zeneca
Pharmaceuticals, Macclesfield, Cheshire, UK).
"Height (pm) mean ± standard deviation In = 7). Data
were assessed for statistical significance by analysis of
variance (10). **p < 0.01 (vs. control). ##p < 0.01 (vs.
COUM).
step) so that a calibration curve could be gem-
erated. From this standard curve the amount
of nucleic acid (in micrograms) in each sam-
ple could be calculated and hence, the
amount ofnucleic acid/mg oftissue could be
determined. Assuming even distributit'on of
nucleic acid throughout the entire uterus, the
amount of nucleic acid (micrograms) per
uterus was then calculated.
Total uterine RNA content was deter-
mined for each tissue sample using the 5%
TCA hydrolysates prepared as described
above (8). Briefly, 250 mL hydrolysate was
mixed with an equal volume of5% TCA and
1 mL orcinol reagent (9). The mixtuire was
heated to 1O00C for 15 mmn and cooled to
room temperature before determining the
OD at 660 nM. Yeast RNA standards were
prepared using the same method as for the
uterine tissue samples (after homogenization)
to generate a standard calibration cuirve. From
this curve the RNA content (in micrograms)
of the uterine horn, and hence the entire
uterus, could be estimated. Total DNA con-
tent was determined bysubtracting this RNA
value from the total nucleic acid estimation as
described above (experiment 2, Table 1).
Statistical assessment ofdata. All data in
Tables 1 and 2 were assessed for statistically
significant differences by analysis ofvariance
(JO). Differences between the groups in their
labeling indices (hyperplasia; Table 3) were
determined by analysis ofvariance following
a double arcsine transformation (11).
Comparisons were carried out separately for
all observations between the control and all
test groups as well as between COUM versus
E2B and, where appropriate, between
COUM versus COUM + FAS.
Results
Uterotrophic assays. The results of the two
experiments conducted are shown in Table
1; experiment 1 is also shown in Figure 1. In
both experiments E2B gave the expected
maximal uterotrophic response at the higher
dose evaluated, and also at the lower dose
used in the second experiment. COUM gave
a positive uterotrophic response of a magni-
tude similar to that reported earlier (4). In
addition, increases in the weights of the
vagina and cervix and in total uterine lumi-
ma1 fluid content were also seen for both
chemicals in both experiments (Table 1).
Coadministration of FAS abolished the
uterotrophic response given by COUM, and
FAS itself led to a significant reduction in
uterine weights, as previously reported (4). A
proportion of the animals treated with E2B
presented with open vaginas at termination
Table 3. Labeling indices inthe immature ratendometrium following treatment with E2B, COUM, or FAS.
Testagent and daily dose level Uterine lumena Glandularepitheliuma Stromaa
AO(5mL/kg) 1.6±0.6(n=6) 4.1 ± 1.3(n-=6) 5.6±3.3
E2B (400 pg/kg) 22.7 ± 13.3**,##, 42.3 ± 14.3**,## 12.2 ± 6.9*
COUM (60 mg/kg) 62.0 ± 8.3 (n- )* 70.0 ± 7.6** 11.1 ± 3.8**
COUM (60 mg/kg) + FAS (10 mg/kg) 2.7 ± 2.9## 2.9 ± 5.0k" 0.7 ±0.3**.##
FAS (110 mg/kg) 1.2 ±0.5 1.3±1.5* 0.8±0.2*
Abbreviations: AO, arachis oil; COUM, coumestrol; E2B, estradiol benzoate; FAS, Faslodex (ICI 182,780; Zeneca
Pharmaceuticals, Macclesfield, Cheshire, UK).
8'Labeling index (%) mean ± standard deviation (n = 7, exceptwhere indicated). Data were assessed for statistical signifi-
cance by analysis of variance following a double arcsine transformation (11). *p < 0.05 (vs. controls); **p < 0.01 (vs. con-
trols); "p <0.01 (vs. COUM).
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Figure 1. Activity of E2B, COUM, and FAS in the immature rat uterotrophic assay. Abbreviations: AG, arachis
oil; COUM, coumestrol; E2B, estradiol benzoate; FAS, Faslodex (ICI 182,780; Zeneca Pharmaceuticals,
Macclesfield, Cheshire, UK). AG was the common vehicle. Data were taken from experiment 1, Table 1. The
total weight of uterine fluid was also calculated. Data are shown as mean weights ± standard deviation.
Environmental Health Perspectives * Volume 107, Number 10, October 199982 821Articles * Ashby et al.
(Table 1), but all AO-, COUM-, and FAS-
dosed animals had closed vaginas.
Determination ofuterine hyperplasia.
Animals treated with E2B (experiment 1) had
significantly increased levels ofBrdU staining
in the endometrium, particularly in the lumi-
nal and glandular epithelium (p < 0.01 vs.
controls in both tissues; Table 3 and Figure
2). Animals treated with COUM showed
similar increases in BrdU incorporation to
those seen with E2B (p < 0.01 vs. controls;
Table 3 and Figure 2). Coadministration of
COUM and FAS inhibited hyperplasia.
Uterine epithelial and endometrial height
paralleled hyperplasia (Table 2).
Detrmination ofuterine DNA content.
Total DNA content of the uteri from ani-
mals in experiment 2 are shown in Table 1.
Animals treated with COUM showed the
same level ofincrease in DNA content as the
animals exposed to the two dose levels of
..~M __
.....
*. ..... .. ....
...... .... .. ~ ~ ~~ ~~~.. ...... ........ -s
AA-
Figure 2. 5-Bromodeoxyuridine immunocytochem-
istry of longitudinal sections of uterus following
treatment with (A) arachis oil (the epithelial cells
are almost cuboidal with few cells in S-phase);
(8) estradiol benzoate (400 pg/kg; columnar
epitheliur.with many cells in S-phase); or (C)
coumestrol (60 mg/lkg narrow columnar epithelial
clls withmn cll ain S-hse)ar5 pm.l
E2B. The average DNA content of control
animal uteri (299.6 + 37.5 pg/total uterus) is
similar to that reported by Markaverich et al.
(1): 217 pg/uterus, as stated in the legend to
their Figure 8.
Discussion
The rodent uterotrophic assay is widely and
increasingly used as a primary assay for estro-
genic activity. Investigators rely primarily on
either the rat or the mouse, and on either
immature intact animals or ovariectomized
animals. Dataderived from assays usinganyof
theseprotocol variants aregenerallyconsidered
qualitatively comparable. Underlying this
beliefis the assumption that increases in uter-
ineweight are always driven byincreased uter-
ine hyperplasia in concert with increased uter-
ine fluid accumulation (imbibation). Within
this context, the report by Markaverich et al.
(1) that the uterotrophic activity of COUM
in the ovariectomized rat assaywas not associ-
ated with an increased DNA content in the
uterus was of obvious interest. Thus, there
may be two distinct mechanisms for the pro-
duction of a positive uterotrophic assay
response-a genuine hyperplastic response
and an atypical response driven by increased
cellular hypertrophy associated only with
increased water imbibation and protein pro-
duction. Markaverich et al. (1) stated that
their findings were in contrast to the reports
of others (2-4) concerning the uterotrophic
activity ofCOUM in immature (intact) rats,
although they also noted that uterine hyper-
plasia and DNA contents had not been deter-
mined in those earlier experiments.
Comparisons between the present data and
those of Markaverich et al. (1) are difficult
because ofthegeneral absence ofprimarydata
in the Markaverich et al. paper. In particular,
the critically important uterine DNA content
data are only presented as a single number in
the legend to their Figure 8. It is probable
that Markaverich et al. (1) used similar dose
levels ofCOUM as those used in the present
study [- 60 mg/kg/day estimated (1) for the
100-jg/mL drinking water experiment]. In
addition, the abscissa in their Figure 8 (hours
after injection) is in error (drinking water
study) and the ordinate in their Figure 10
should read uterus wet weight and not estro-
gen receptorsites percell (1X).
As part ofasmallvalidation ofthe rodent
uterotrophic assay we recently described the
positive uterotrophic activity of COUM in
immature intact rats (4). We assumed at that
time that this response was mediated by
increased uterine hyperplasia and DNA syn-
thesis, although thatwas not established. The
present experiments have confirmed that the
trophic activity of COUM to the intact
immature rat is evident for both wet and dry
uterine weights and for wet weights of the
cervix and vagina. Further, uterine fluid
imbibation is increased, the effects are medi-
ated via the estrogen receptor, and they are
accompanied by increases in uterine hyper-
plasia and total uterine DNA content. In
fact, the uterotrophic response elicited by
COUM was identical to that induced byE2B
in all ofthese respects.
These data therefore indicate a possible
difference between the immature intact rat
uterotrophic response to COUM and the
ovariectomized rat uterotrophic response to
COUM. However, before thatconclusion can
be drawn with anyconfidence itwill be neces-
sary for the original observations reported by
Markaverich et al. (1) to be confirmed and
extended. This is necessary because those
observations were limited in respect to thecrit-
ical absence ofa hyperplastic response of the
uterus to COUM. In particular, uterine
hyperplasiawas neither assessed histopatholog-
ically norwith the aid ofa marker ofcell divi-
sion (such as BrdU incorporation). Rather,
reference was made only to a single uterine
DNAcontent figure, and then only in theleg-
end to one ofthe figures in the paper [Figure
8; (1)]. Such a repeat experimentwas not con-
ducted as part ofthepresent studies because of
the scarcity and expense ofCOUM, especially
given the larger quantities that would be
required for the conduct of mature ovariec-
tomized ratuterotrophic assays.
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